Skip to Content

Yet Another Alzheimer’s Treatment Fails in Large Trial

A mixed-antibody treatment does not protect patients from cognitive decline.

More bad news from drugmakers trying to develop treatments for Alzheimer’s disease: Yesterday, Baxter announced that its mixed-antibody therapy failed to reduce cognitive decline in patients with mild to moderate Alzheimer’s disease. As I reported back in July 2012, the company saw positive results in a small four-patient trial of the treatment. None of these patients showed any cognitive decline, leading some experts to hope that the disease can be stopped or slowed (see “Study Suggests Alzheimer’s Disease Can be Stabilized”). But when Baxter tested its potential treatment—a complex mixture of antibodies harvested from healthy donated blood—in nearly 100-times as many Alzheimer’s patients, the company did not find a rate of decline slower than patients given a placebo.

Baxter’s announcement comes less than a year after two other pharmaceutical companies revealed that their Alzheimer’s treatment candidates failed in large clinical trials (see “Another Bust for Alzheimer’s Drugs” and “A New Setback for Alzheimer’s Drugs”). Both of these company’s trials tested antibodies known to glom onto the plaque protein amyloid-beta (it’s not clear what protein, or proteins, Baxter’s mixed antibody treatment would target). What drug makers are getting wrong is not clear—it could be  timing (many experts believe treatments will need to start early in the course of the disease, perhaps even before cognitive decline begins, to be effective), or it could be that amyloid is not the right target (the cause of the disease and amyloid’s role are not set in stone). What is clear is that with each year, we are facing a larger problem: Currently, around 36 million people worldwide have Alzheimer’s. That number is expected to grow to 2 billion by 2050 (see “The Dementia Plague”).

Keep Reading

Most Popular

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

biomass with Charm mobile unit in background
biomass with Charm mobile unit in background

Inside Charm Industrial’s big bet on corn stalks for carbon removal

The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.

AGI is just chatter for now concept
AGI is just chatter for now concept

The hype around DeepMind’s new AI model misses what’s actually cool about it

Some worry that the chatter about these tools is doing the whole field a disservice.

Peter Reinhardt
Peter Reinhardt

How Charm Industrial hopes to use crops to cut steel emissions

The startup believes its bio-oil, once converted into syngas, could help clean up the dirtiest industrial sector.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.